by Doug Donovan, Johns Hopkins University Credit: Pixabay/CC0 Public Domain It’s shaping up to be a big week for news on two eagerly awaited developments involving Pfizer’s COVID-19 vaccine: Booster shots and progress toward its first doses for children as young as five. The Food and Drug Administration is set to decide whether to accept its...
Credit: Pixabay/CC0 Public Domain Pfizer and BioNTech on Monday submitted preliminary clinical data to US health authorities as part of their effort to seek authorization for a third dose of their COVID-19 vaccine for all Americans. Last week, the United States approved the booster shot of Pfizer-BioNTech and Moderna vaccines for people with weakened immune systems. Pfizer...
by Amanda Ferguson, University of Toronto Credit: Unsplash/CC0 Public Domain Early results from a new study led by researchers from the University of Toronto and Sinai Health reveals subtle differences between the immune responses of long-term care residents receiving the Pfizer-BioNTech and Moderna vaccines. The research, which has not yet been peer-reviewed, suggests that long-term care residents in Ontario...
By Dr. Liji Thomas, MD May 19 2021 Reviewed by Emily Henderson, B.Sc. With the controversy surrounding the dosing interval for the Oxford Astra-Zeneca vaccine against coronavirus disease 2019 (COVID-19), a new preprint published on the pre-print server medRxiv* discusses the results of a study of antibody responses to the first and second dose of two currently...
Colorized scanning electron micrograph of a cell (blue) heavily infected with SARS-CoV-2 virus particles (red), isolated from a patient sample. Image captured at the NIAID Integrated Research Facility (IRF) in Fort Detrick, Maryland. Credit: NIAID The head of Pfizer said in an interview aired Thursday that people will “likely” need a third dose of his company’s COVID-19...
TOPLINE Drugmakers Pfizer and BioNTech asked U.S. regulators on Friday to make their Covid-19 vaccine the first authorized for Americans under the age of 16, after preliminary data suggested the shot is 100% effective at staving off illness in teens ages 12 to 15. KEY FACTS New York City-based Pfizer and Germany’s BioNTech are asking...
By Rich Haridy February 21, 2021 New data suggests Pfizer’s COVID-19 vaccine is stable for at least two weeks under normal freezer temperaturesBioNTech VIEW 1 IMAGES New data submitted to the U.S. Food and Drug Administration from Pfizer claims its mRNA COVID-19 vaccine is stable for longer periods at warmer temperatures than previously thought. The...
Credit: Pixabay/CC0 Public Domain The first dose of the Pfizer vaccination is 85 percent effective against coronavirus infection between two and four weeks after inoculation, according to a study published in the Lancetmedical journal. The survey was carried out on healthcare workers at the largest hospital in Israel, which on December 19 launched a mass vaccination...
Jason Mast Editor When the FDA approved Pfizer’s JAK inhibitor Xeljanz for rheumatoid arthritis in 2012, they slapped on a black box warning for a laundry list of adverse events and required the New York drugmaker to run a long-term safety study. That study has since become a consistent headache for Pfizer and their blockbuster...
by Lauran Neergaard In this Friday, Dec. 11, 2020, file photo, a Pfizer Global Supply Kalamazoo manufacturing plant sign is shown in Portage, Mich. New research suggests that Pfizer’s COVID-19 vaccine can protect against a mutation found in two contagious variants of the coronavirus that erupted in Britain and South Africa. Those variants are causing...
